Pharmaceutical Manufacturing in Sweden

Pierre Fabre Pharma Norden Ab

Pierre Fabre Pharma Norden is situated with the head office in Stockholm, Sweden. We belong to Laboratoires Pierre Fabre which is a French multinational pharmaceutical and cosmetics company. It is headquartered in the city of Castres, Midi-Pyrénées, France. Founded in 1962 by Pierre Fabre (1926-2013), the company is present in over 130 countries. The Pierre Fabre Group is characterized by a strong culture forged by our founder, Pierre Fabre, and has always been based on the values of rigor, integrity, responsibility, citizenship and respect for humans and the environment. Websites: Questions regarding our medicines: infonorden@pierre.fabre.com To report side effects, follow the link: Contact information Pierre Fabre Pharma Norden AB Karlavägen 108, 9 tr 115 26 Stockholm Phone:+46 8 625 33 50 Email: infonorden@pierre-fabre.com

11 to 50 staff

Rechon Life Science Ab

Rechon Life Science AB is a pharmaceuticals company based out of 108Limhamnsvägen, Malmö, Skane County, Sweden.

201 to 500 staff

Allderma Pharmaceuticals

Allderma är ett svenskt läkemedelsbolag som marknadsför och distribuerar läkemedel och medicintekniska produkter inom dermatologi på den nordiska marknaden. Vi arbetar kontinuerligt för att genom kvalitet och innovation erbjuda patienter och vården det bästa vårdalternativet.

11 to 50 staff

Ascelia Pharma Ab

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (former working name Mangoral) and Oncoral – in clinical development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). About Orviglance (Mangoral) Orviglance*(manganese chloride tetrahydrate) is a novel oral contrast agent for MR-imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function. These patients are at risk of serious side effects from the currently available class of gadolinium-based contrast agents. Orviglance, which has been granted an Orphan Drug Designation by the US Food and Drug Administration (FDA), is currently in Phase 3 development, including the global multi-center SPARKLE study. About Oncoral Oncoral is a novel oral irinotecan tablet in development. Irinotecan is a chemotherapy with established potent anti-tumor effect – even in difficult to treat cancers. Oncoral is a daily tablet with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital. Oncoral is initially developed for the treatment of gastric cancer, a cancer form with unmet needs and the opportunity for Orphan Drug status in the US and Europe. Following successful Phase 1 results, Phase 2 clinical development for Oncoral is in preparation.*Trademark is registered in Europe and several other markets and submitted for registration in the US.

11 to 50 staff

Calliditas Therapeutics

Calliditas is a specialty pharmaceutical company developing high value products for patients with significant unmet medical needs. With a highly experienced, dynamic management team, Calliditas draws on its extensive experience of pharmaceutical development and marketing to efficiently identify and progress valuable and de-risked products.

51 to 200 staff

Clientelis

Clientelis helps pharma teams reach and engage doctors instantly, globally, and compliantly — at a fraction of the cost of traditional field or digital channels. Our AI MedReps platform delivers: Higher HCP reach across markets and specialties Faster product education and adoption Consistent medical communication across brands and geographies Reliable compliance, even at scale Significantly lower cost per interaction compared to reps, MSLs, email, or portals Pharma teams use Clientelis to accelerate launches, expand brand penetration, reactivate inactive doctors, and maintain compliant medical conversations across WhatsApp, iMessage, and other mobile-native channels. We support global medical, digital, and commercial teams. Our mission: make high-quality, compliant doctor engagement instant, scalable, and globally accessible.

11 to 50 staff

Dicot Pharma Ab

Dicot is a pharmaceutical company focused on increasing quality of life and well-being through innovations that enhance sexual health. The company develops and manufactures medicines for the treatment of erectile dysfunction and premature ejaculation. The company's lead candidate, LIB-01, is in clinical stage of development.

1 to 10 staff

Enorama Pharma

Enorama Pharma AB is a Swedish pharmaceutical company based in Malmö, with a fully owned US subsidiary in Florida. The company has since 2016 been listed on Nasdaq First North Growth Market in Stockholm. Enorama Pharma is focusing on the development and manufacturing of consumer-friendly, oral nicotine products, such as nicotine white pouches under the brand name NIC-S® and nicotine chewing gum (medicinal).

1 to 10 staff

Infant Bacterial Therapeutics Ab

Infant Bacterial Therapeutics AB (IBT) is a pharmaceutical company dedicated to developing drugs that prevent diseases in premature infants and combat the spread of antibiotic-resistant illnesses. IBT’s primary focus is on IBP-9414, a drug candidate containing Lactobacillus reuteri, a bacterial strain found in breast milk. The aim of IBP-9414 is to reduce the occurrence of necrotizing enterocolitis (NEC) and improve sustained feeding tolerance (SFT) in premature infants. Currently, IBP-9414 is undergoing a pivotal Phase study for registration. IBT also has other drug candidates, including IBP-1016 for treating gastroschisis, for preventing retinopathy of prematurity (ROP), and IBP-1122 for eliminating vancomycin-resistant enterococci (VRE) causing hospital acquired infections. By developing these drugs, IBT addresses medical needs that lack available treatments.

1 to 10 staff

Nordic Market Access Nma

Market access consulting

1 to 10 staff

Pharma Way Ab

Pharma Way is a foodtech company that develops, markets and sells innovative and effective health products in the European and North American market. The products are based on unique knowledge to develop and formulate water-based herbal extracts with improved health effects for beverages with good taste. The goal is to become a market leader in this area with our products.

1 to 10 staff

Novavax Ab

Novavax AB is a fully owned subsidiary of Novavax Inc. a late-stage biotechnology company focused on the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Product Pipeline Our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("RSV"), seasonal influenza, pandemic influenza, and Ebola virus ("EBOV"). We have additional preclinical-stage programs for a variety of infectious diseases. Corporate Overview Novavax is headquartered in Gaithersburg, Maryland with additional facilities in Rockville, Maryland and Uppsala, Sweden. Novavax is traded on the Nasdaq Stock Market under the symbol NVAX and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.

201 to 500 staff

Attgeno

Attgeno, home of Supernitro, is a Swedish clinical stage pharmaceutical company founded by a research group at the Karolinska Institute, Stockholm, to develop and bring to market new nitric oxide (NO)-donating technology and products. Our first drug candidate, Supernitro, is based on a novel principle developed by Attgeno and is intended to reverse life-threatening high blood pressure in the lungs (acute pulmonary hypertension, aPH).

1 to 10 staff

Circius Pharma

Circius Pharma is an international and growth oriented pharmaceutical and MedTech company. From our base in Sweden we develop strong brands and patient-centered products for the global market.

11 to 50 staff

Gabather

Gabather (abbreviated form of GABA Therapeutics) focuses on the development of highly potent and selective GABAA receptor modulators targeting the principal inhibitory neurotransmitter in the mammalian brain, gamma aminobutyric acid (GABA). Our drug development candidates are small molecular weight compounds designed through proprietary pharmacophore modelling. Our development pipeline includes candidates targeting the GABAA receptor in both preclinical and clinical development and we aim to produce novel pharmaceuticals such as antipsychotics, antidepressants, anxiolytics, analgesics and cognitive enhancers to treat CNS diseases with high unmet need.

1 to 10 staff

Incepta Consulting Ab

Incepta är ett konsultbolag som kan projektledning och kvalitetssäkring i hårt kravställda miljöer inom privat och offentlig sektor. Med en pådrivande personlighet tar vi initiativ till en miljö där man möts, diskuterar och samarbetar. Våra konsulter har genomgående kvalitetstänk och en hög operativ och affärsmässig förståelse. Genom erfarenhet och bredd från olika kunder tillför vi kompetens och nya perspektiv, med målet att ge mervärde till kundens organisation.

1 to 10 staff

Index Pharmaceuticals Ab

InDex Pharmaceuticals in brief InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate cobitolimod, which is being evaluated in the phase study CONCLUDE as a novel treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases. InDex is based in Stockholm, Sweden. The company’s shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm.

11 to 50 staff

Modsim Pharma

Welcome to MODSIM Pharma - Optimizing Drug Discovery through Computational Chemistry. At MODSIM Pharma, we specialize in Structure-Based Drug Design with our physics-based proprietary methods and molecular simulations to optimize the Drug Discovery process. Born from groundbreaking research at Uppsala University, we integrate advanced algorithms with machine-learning/AI capabilities to help companies accelerate the Hit Identification, Hit-to-Lead and Lead Optimization stages of their drug discovery processes. Our optimized molecular simulations and free energy calculation pipelines minimize computational costs. We offer flexible software licensing, computing services, scientific development and expert consulting. Contact us to learn how we can accelerate your Drug Discovery journey.

1 to 10 staff

Nanexa Ab

Nanexa AB is a drug delivery company that focuses on the development of PharmaShell®, a new and pioneering drug delivery system that is considered to have great potential in a number of substance types and indication areas. Within the framework of PharmaShell®, Nanexa develops its own projects and has collaborative agreements with several pharmaceutical companies, including AstraZeneca.

11 to 50 staff

Neuraxpharm

Neuraxpharm is a leading European specialty pharmaceutical company focused on the treatment of the central nervous system (CNS), including both psychiatric and neurological disorders, with a unique understanding of the CNS market. Neuraxpharm is constantly innovating, with new products and solutions to address unmet patient needs and is expanding its portfolio through its pipeline, partnerships, and acquisitions. The company has employees and develops and commercialises CNS products through a direct presence in more than 20 countries in Europe, two in Latin America, one in the Middle East, one in Australia, and globally via partners in more than 50 countries. Neuraxpharm is backed by funds advised by Permira. Neuraxpharm manufactures many of its pharmaceutical products at Neuraxpharm Pharmaceuticals (formerly Laboratorios Lesvi) in Spain. To learn more about Neuraxpharm, please visit

1001 to 5000 staff

Pharmaceutical Student Association

The Pharmaceutical Student Association is a student union at the Faculty of Pharmacy at Uppsala University. The Association was founded in Stockholm in 1896. The association has approximate one hundred student volunteers who works with the main goal to improve the pharmaceutical education, the student social life and to establish and maintain the collaboration between student and professionals in the healthcare sector in Sweden.

51 to 200 staff

Qalliance

Welcome to QAlliance – where quality is not just a goal; it's an integral part of the journey. Our approach is simple yet profound – we call it 'Working Quality.' It's about nurturing an environment where excellence becomes second nature, where quality is not a constraint but a catalyst for growth and success. With our expertise within GLP, GDP, GMP and GCP, and our dedication to Working Quality, we will help you foster a culture of continuous improvement, where quality becomes a habit and innovation flourishes without compromise.

1 to 10 staff

Renapharma Ab

The company was founded in by prof. Bo G Danielson. Today we are focusing on treatment of vitamin D deficiency and to provide iron supplementation for people in need of iron supplementation in the Nordic countries. The company was originally founded in Uppsala but is now located in Stockholm.

1 to 10 staff

Synartro

Synartro is a Swedish pharmaceutical company developing local injection treatments aiming to provide superior and sustained efficacy without systemic side-effects. This is achieved by combining our patented delivery technology with existing proven drugs. Our pre-clinical lead program focuses on a novel therapy using our compound SYN321 for the treatment of osteoarthritis (OA). Currently this disease leaves up to 50% of patients without adequate pain relief.

1 to 10 staff

Tirmed Pharma

TIRmed Pharma´s product candidate is a chemically stabilized, single-stranded oligonucleotide, which has non-coding and non-complementary sequence. The compound is formulated in a cream aiming for a self-applied and easy to use at-home anti-itch treatment. The product through its mode-of-action, which saves vital immune defenses and has anti-itch effects, would have potential for safe and effective treatment of mild to moderate atopic dermatitis. Atopic dermatitis is associated with a disrupted skin barrier facilitating entry of external allergens and compounds for treatment. Topical delivery to the skin limits systemic adverse events. TIRmed´s cream is intended for early mild-moderate symptoms to limit the use of biologicals.

1 to 10 staff

Zelmic Ab

Zelmic – Experts in Topical Drug Development Zelmic is a specialized CRO and CDMO based in Lund, Sweden, at the heart of Medicon Valley – one of Europe’s leading life science hubs. We are unique in focusing exclusively on topical pharmaceuticals – creams, gels, ointments, solutions, and lotions. Our mission is simple: to provide fast, flexible, and science-driven support to biotech and pharma companies worldwide developing innovative and generic topical drugs. With our GMP manufacturing facility and MIA license, we provide EU-compliant clinical trial material (CTM) manufacturing and importation, ensuring a seamless path to First-in-Human and beyond. Our core expertise-Formulation development – from pre-formulation and excipient screening to optimization of creams, gels, and ointments -Analytical development and validation – including ICH stability studies, forced degradation, method development & GMP QC testing -Performance testing (IVRT & IVPT) – bioequivalence and skin penetration studies for both innovative and generic topical drugs -CMC & regulatory support – IMPD preparation, EU guidance, and QP release-Reverse engineering & reformulation – deformulation, scale-up, and tech transfer for topical generics -GMP manufacturing & importation (MIA licensed) – small-scale and clinical trial batches produced and imported under EU GMP Why Zelmic-100% focus on topical drug delivery – no distractions, only deep expertise -Based in Lund, Sweden (Medicon Valley) – connecting Nordic biotech with global pharma -Fast, flexible, and personal – unlike larger CROs/CDMOs, we adapt to your needs -Integrated CRO + CDMO offering – seamless path from R&D to clinical supply -MIA licensed – ensuring EU-compliant manufacturing, importation, and QP release

1 to 10 staff

2care4 Group

2care4 was founded in 2005. Since then we have built solid experience in parallel import of pharmaceutical products within human medicine in the EU/EEA countries. The key to our success lies in our values, which we strive to live up to every single day. These values have helped us evolve from a small, local entrepreneurial company into one of the largest suppliers of pharmaceuticals to the Scandinavian markets. 2care4´s headquarter is located in Esbjerg, Denmark with sales offices in Sweden and Germany, and repacking facilities in Europe. Since 2005, the 2care4 Group has focused on the Nordic and German pharmaceutical markets within parallel imports and since 2010 also within generic development and trade. In the pursuit of a good working environment and constant focus on relationships and dedication, the group has grown to employ more than 300 people throughout Europe.

201 to 500 staff

Acucort Ab

AcuCort has developed and commercializes Zeqmelit™, a new fast-dissolving oral film to put on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly dosage form primarily for the treatment of severe and acute allergic reactions, croup in children and chemotherapy-induced nausea and vomiting (CINV) and for the treatment of patients with COVID-19 who need supplemental oxygen therapy. Zeqmelit™ is approved in Sweden, Denmark, and Norway; and AcuCort has signed its first commercial agreement. Altogether, this strengthens the company’s assessment that the time to commercialization may be relatively short. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market in Sweden. Please visit

1 to 10 staff

Addeira Pharmaceuticals

Addeira Pharmaceuticals AB is a Swedish pharmaceutical and medical device company committed to the development and commercialization of a whole range of new self-care products and prescribed pharmaceuticals for the Nordic pharmacy retail market and hospitals. With our background as pharmacists, the well-being of customers are always our most important priority; that the right medical need is matched with the right product and the right advice. To constantly work to improve both treatment and care. But we have also experienced that it can be difficult for customers to understand the difference between pharmacy products and that they may not work as well as one would like. It made us take off our white coat, at least for a while, and to try to find better and more effective medical alternatives. Today, we can offer a range of innovative self-care products, developed in close dialogue with pharmacies and always striving for a sustainable production. Each product has its own unique reason why it exists, but the common denominator is that everyone should contribute with a new function or a better effect. With a little innovation and a bit of perseverance, we are proud to be able to contribute to a developed self-care. If we can improve the health of just one individual, we can free up time for the healthcare system, which also makes it better in the end. Addeira Pharmaceuticals AB was founded in 2019 by two pharmacists. Caring, curiosity and optimism are our path to a better well-being for the individual, healthcare and society at large.

1 to 10 staff

Disruptive Pharma

Disruptive Pharma is an innovative clinical stage biotech and drug delivery company leveraging innovative its mesoporous magnesium carbonate (MMC) technology to enable amorphous drug formulations. Our cutting-edge MMC technology enables the transformation of pharmaceutical assets — APIs, NCEs, or development opportunities — into differentiated, commercially attractive drug products. With the recent advancement of our first product candidate into the clinical stage, we are now entering the scale-up phase, further demonstrating the potential of MMC in real-world drug development. The MMC technology produces stable amorphous formulations with optimal drug product characteristics, making it attractive solution for differentiation, for enablement of novel drugs and in lifecycle management strategies. An MMC amorphous drug simplifies development and optimizes product characteristics. Disruptive Pharma are seeking corporate relationships with biotech and pharmaceutical companies to create additional value across our product portfolio, pre-clinical candidates and MMC technology offerings.

11 to 50 staff

Medaffcon

Medaffcon is a Nordic research and consulting company specializing in Real-World Evidence, Medical Affairs, and Market Access. With offices in Stockholm, Sweden, and Espoo, Finland, we provide expert services across the Nordic region. Medaffcon was founded in 2009. Since 2017 we have been a part of PHOENIX Group, European leader in pharmaceutical wholesale, pharmacy retail, and services for the pharmaceutical industry. Our expertise extensively represents the fields of Health Economics, Medical and Natural Sciences as well as Data Sciences. We are thoroughly acquainted with the processes in the field and we can take over different projects even on a short-term schedule. Our solutions are always tailored to the customer’s needs. Our services include- Real World Evidence based studies - Pricing and reimbursement processes - Treatment path and stakeholder mapping - Health economic modelling - Expert resourcing - Managed entry agreements - Training Interested to hear more? Visit our website or send us an email at info@medaffcon.com

11 to 50 staff

Pharmadule Morimatsu Ab

As the founder of the modular delivery concept for pharmaceutical facilities, Pharmadule started its business in Stockholm, Sweden in 1986. Since the start, more than 80 projects have been delivered using Pharmadule's modular facility concept. Leading global pharma companies are using the modular approach for their new manufacturing facilities worldwide. Since 2011, Pharmadule is part of Morimatsu Group, an international manufacturer of process equipment and modular process super skids. This strong combination has allowed Pharmadule Morimatsu to combine process equipment with modular facilities for delivery of turnkey solutions to our clients. Today, Morimatsu Group is a world leader in the delivery of innovative process solutions and modular facilities with more than 4,100 global employees. The Group has sales and engineering offices in Stockholm, Shanghai, Wuhan, Yokohama, New Jersey, Houston, Milano, Dublin and Mumbai. Pharmadule Morimatsu has a strong global presence with our engineering and manufacturing facilities in Shanghai, Japan and Malaysia. Today, Pharmadule Morimatsu designs and delivers modular projects to the Life Sciences and Consumer Products industries. The Pharmadule Way offers unique values.

501 to 1000 staff

Vironova Medical Ab

Vironova Medical AB was founded in 2015 as a spin-out from Vironova AB by Mr Mohammed Homman and the late Prof. Jan Bergman. Vironova Medical is commercializing a patented chemical process technology for thionation named Jan Bergman Reagent, “JBR” after its inventor. We are using JBR in the development of pharmaceuticals including antiviral compounds, that make up part of our portfolio and compound library.

1 to 10 staff

Atrogi

We are a clinical-stage biotech company pioneering first-in-class treatments to revolutionize metabolic health. Our mission is to redefine the management of diabetes, obesity, and other metabolic diseases, by harnessing the potential of small molecules with distinct and novel signaling profiles.

1 to 10 staff

Beactica Therapeutics

Beactica Therapeutics is a specialist drug discovery and development company, committed to the fight against cancer. Beactica is advancing a proprietary pipeline of first-in-class therapeutics by applying its molecular interaction-based drug discovery engine synergistically across multiple small molecule modalities – including allosteric modulators, protein–protein interaction inhibitors and targeted protein degraders (PROTACs).

11 to 50 staff

Beaphar Nordics

Beaphar er en trendsettende utviklings, produksjons- og markedsførings-organisasjon med et bredt spekter av helse-og pleieprodukter til kjæledyr. Selskapet ble etablert i 1943 av Mr. Bernard Aa, og er fortsatt fullt ut familieeid. Gjennom sin brede base verden over, tar Beaphar opp en sterk konkurranseposisjon i både det Europeiske og globale markedet. Beaphar sine produkter distribueres i 86 land over hele verden, gjennom eksklusive distributører med egne salgskontorer i Belgia, Frankrike, Nederland, Storbritannia, Tyskland, Polen, Tsjekkia, Norge, Italia, Ungarn, Hellas, Australia, Spania og Hong Kong. Vårt utvalg omfatter over 800 forskjellige produkter som er eksklusive for faghandelen, og som omfatter alt fra helseprodukter til superpremium fullfôr. Kjernen i selskapet er utvalget av legemidler, flått- og loppekontroll, markkurer, antibiotika- og vitaminpreparater. Kort sagt: Beaphar har alt som er spesielt til ditt kjæledyr.

1 to 10 staff

Corline Biomedical Ab

Medical Device Coatings and Drug development to improve outcome of kidney transplantation.

11 to 50 staff

Essbay Ab

Pharmaceutical growth with precision - Essbay offers advisory services to the biopharma industry. What are the necessary steps to optimize the value of your product at any stage in the product lifecycle? How do you ensure that your product in development meets the expectations of all stakeholders at each step of the journey- Offering development and management - Are you in the business of supporting the biopharma industry with products or services? How do you best position your product and what needs does it fulfill? An optimal client segmentation and targeting in conjunction with the optimal go-to-market strategy is difficult to achieve even if you know the industry. Essbay offers more than a decade of experience in getting it right- Connect the dots - With an extensive network of business contacts worldwide, Essbay can help you connect the dots between you and potential collaboration partners. It is relatively rare that working in isolation is the best way forward. Your product or service is quite likely to fit well with other offerings or players on the market. Be it sales, marketing or synergetic alliances.

1 to 10 staff

Exeltis Nordics

A step forward in improving health: Exeltis is the result of the natural evolution and sustained growth of the Insud Pharma pharmaceutical business, an integrated health sciences group. It combines the Group’s know-how and experience with the innovative spirit of Exeltis, becoming a global organization with the capacity to discover, develop, produce and market medicinal products and medical devices that can help to improve the quality of life of millions of people worldwide. Exeltis Nordics was established in 2016 and has commercial presence in all Nordic countries. Partner to gynaecologists and midwives, we contribute to women's health and well-being in all stages of their life.

11 to 50 staff

Farmacia Nordic

Farmacia Nordic är ett privatägt svenskt läkemedels- och medicintekniskt bolag, som främst arbetar nordiskt men har ett brett europeiskt kontaktnät. Vi har lång och gedigen erfarenhet inom läkemedelsindustrin med mycket samlad kunskap och kompetens. På nordisk basis har vi både sälj- och marknadsavdelning samt medicinsk och regulatorisk avdelning.

1 to 10 staff

Gnothis Ab

1 to 10 staff

Icoat Medical Ab

iCoat Medical is a clinical stage, immunotherapy company focusing on reducing and preventing ischemia reperfusion injuries by developing novel pharmaceutical products. The company is one of the world’s leading R&D-centered organizations within innate immunology and is systematically expanding its pipeline using its proprietary coating-technology platform. iCoat Medical’s lead candidate TUM012 is developed to improve the outcome of organ transplantations. iCoat Medical’s unique ex-vivo coating of the grafts has the ambition of being an integral part in the transplant procedures of tomorrow. iCoat Medical has operations in Uppsala, Lund and Malmö, and is headquartered in Stockholm.

11 to 50 staff

Novelmedic Ab

Novelmedic AB is contract manufacturer with focus on liquid and aseptic production, providing products to the pharmaceutical industry, life science market and to pharmacies. The production site is located in Södertälje, south Stockholm, Sweden in a newly rebuilt production facility previously owned by AstraZeneca. Our production capacity is flexible to the customer demands and we always try to exceed customer expectations with quality of excellence, Novelmedic puts the customer need in focus. The facility and the equipment are flexible and can be adapted for the production of both medium and small scale.

1 to 10 staff

Ptc Therapeutics Nordics, Baltics & Benelux

PTC is a science-led, patient-centered biopharmaceutical company focused on discovering, developing and commercializing medicine for patients with rare disease. This page is for the NBB region (Nordics, Baltics & BeNeLux)

501 to 1000 staff

Synergus Rwe

Synergus RWE is dedicated to developing and executing RWE strategies for decision makers in Europe.

1 to 10 staff

Xinnate

Xinnate is a pharmaceutical development company in Lund, Sweden developing novel, pharmaceutical therapies based on a pioneering technology of immune modulating peptides, that targets dysfunctional healing by controlling presence of microbials and the complex interplay of inflammatory responses. Xinnate runs an ambitious research and clinical program for TCP25 including a clinical study in phase 1b in patients with Epidermolysis bullosa (EB). Late-stage clinical development and commercialization will take place in partnership with one or more leading pharmaceutical companies.

1 to 10 staff

Aqua-Nova Ab

Always in the fore front for new developments' AQUA-NOVA® Water Stills and Pure Steam Generators represent more than 30 years of accumulated experience within WFI production and clean water systems. Our third generation Multi- and Single-effect Stills are characterized by flexible operation and a safe distillate quality exceeding the specifications of USP, EP and JP for "Water For Injection". The stills can also produce Pure Steam for sterilisation purposes. Depending on the needs for Pure Steam the units are individually dimensioned to meet the requirements in each case. Of special importance in our designs is the water droplet separation in four steps, introduced in 1980 The developed "float" type heat exchangers minimizes the thermal stress thus avoiding formation of micro cracks. The thermosiphon principle used gives high efficiency and reduces possible scaling should the feed water deteriorate. A variety of optional equipment are available with all units and the instrumentation can be adapted to the client´s in-hose standards. The software programs are developed following the GAMP guidelines. AQUA-NOVA® Multi-effect stills with 4 step seperation and proportional regulation giving maximal operation reliability. AQUA-NOVA® COMBI multi-effect still for simultaneous WFI and Pure Steam production at any capacity. AQUA-NOVA® Pure Steam Generators as "stand-alone" units AQUA-NOVA® Laboratory Stills & MEDICELL® AQUA-NOVA® PW and HPW systems

1 to 10 staff

Cormorant Pharmaceuticals

Cormorant Pharmaceuticals is a recently founded biopharmaceutical company focusing on the development of therapeutics for the treatment of cancer and rare diseases. Cormorant Pharmaceuticals’ business model is based on the principle of combining new research findings with existing drug substances in order to bring innovation faster to the patient. The company is privately held and based in Stockholm, Sweden Currently, we our IL-8 antibody HuMax-IL8 is being tested in a phase I trial in patients with solid tumors. Our vision for this project is that the inhibition of IL-8 will target the aggressive behaviour of cancer cells and cancer stem cells in several cancer forms. IL-8 inhibition also has the potential to reduce tumor immunosuppression through MDSCs (myeloid derived suppressor cells). HuMax-IL8 will be a first in class agent with possibility to target many different tumor types and to be combined with other treatments, due to a good safety profile.

1 to 10 staff